The FDA said it would take “decisive steps” to restrict non-approved drugs that use GLP-1 active pharmaceutical ingredients.

By Leah Douglas and Siddhi Mahatole Feb 6 (Reuters) - The U.S. Food and Drug Administration said on Friday it would take ...

By Amina Niasse NEW YORK, Feb 5 (Reuters) - Online telehealth company Hims and Hers Health on Thursday began offering a much ...

Food and Drug Administration targets Hims & Hers after telehealth company undercuts Novo Nordisk on obesity shot ...

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill Wegovy.

The target action date for orforglipron is now April 10.

Hims & Hers Health, Eli Lilly, and Novo Nordisk shares all slid Thursday after Hims & Hers said it would start selling a ...

(The Hill) – The Food and Drug Administration (FDA) has approved Novo Nordisk’s oral version of the Wegovy weight-loss pill, the first such supplement approved for use. Novo Nordisk said in a Tuesday ...

In December 2025, the U.S. Food and Drug Administration gave the green light to a pill version of the blockbuster weight loss drug Wegovy, the first FDA-approved daily oral GLP-1 medication for ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: You can get semaglutide injections (Ozempic® and Wegovy®) and oral semaglutide (Rybelsus®). Injections are usually more ...

The rebound followed sharp declines earlier in the week, including a near-8% drop on Thursday after telehealth firm Hims and ...

Novo Nordisk shares rose by more than 5% after scrutiny of Hims & Hers Health's compounded semaglutide pill following an FDA ...